IcyAlchemist
2021-11-30
Like and comment
ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609675925,"tweetId":"609675925","gmtCreate":1638283546171,"gmtModify":1638283546291,"author":{"id":3586429646894350,"idStr":"3586429646894350","authorId":3586429646894350,"authorIdStr":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment</p></body></html>","htmlText":"<html><head></head><body><p>Like and comment</p></body></html>","text":"Like and comment","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609675925","repostId":1174359019,"repostType":4,"repost":{"id":"1174359019","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638282153,"share":"https://www.laohu8.com/m/news/1174359019?lang=&edition=full","pubTime":"2021-11-30 22:22","market":"us","language":"en","title":"ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1174359019","media":"Tiger Newspress","summary":"ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatm","content":"<p>ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatment met the primary goals of a late-stage study.</p>\n<p><img src=\"https://static.tigerbbs.com/77ef54f585fc3671ff475aa8ed50d2be\" tg-width=\"850\" tg-height=\"819\" referrerpolicy=\"no-referrer\"></p>\n<p>ImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed objective response rate (ORR) of 32.4%, the drugmaker said, with a duration of response of 5.9 months in the 106-person trial.</p>\n<p>ImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.</p>\n<p>\"This is an exciting moment, both for the field of ovarian cancer and for ImmunoGen, and the outcomes from SORAYA further validate our longstanding history of innovation in ADCs,\" said ECEO Mark Enyedy. \"We are moving forward expeditiously to complete the BLA for mirvetuximab, with the goal of submitting the application to FDA for accelerated approval in the first quarter of 2022. In parallel, commercial preparations are well underway to support the potential launch of mirvetuximab next year.\"</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-30 22:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatment met the primary goals of a late-stage study.</p>\n<p><img src=\"https://static.tigerbbs.com/77ef54f585fc3671ff475aa8ed50d2be\" tg-width=\"850\" tg-height=\"819\" referrerpolicy=\"no-referrer\"></p>\n<p>ImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed objective response rate (ORR) of 32.4%, the drugmaker said, with a duration of response of 5.9 months in the 106-person trial.</p>\n<p>ImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.</p>\n<p>\"This is an exciting moment, both for the field of ovarian cancer and for ImmunoGen, and the outcomes from SORAYA further validate our longstanding history of innovation in ADCs,\" said ECEO Mark Enyedy. \"We are moving forward expeditiously to complete the BLA for mirvetuximab, with the goal of submitting the application to FDA for accelerated approval in the first quarter of 2022. In parallel, commercial preparations are well underway to support the potential launch of mirvetuximab next year.\"</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMGN":"ImmunoGen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174359019","content_text":"ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatment met the primary goals of a late-stage study.\n\nImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed objective response rate (ORR) of 32.4%, the drugmaker said, with a duration of response of 5.9 months in the 106-person trial.\nImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.\n\"This is an exciting moment, both for the field of ovarian cancer and for ImmunoGen, and the outcomes from SORAYA further validate our longstanding history of innovation in ADCs,\" said ECEO Mark Enyedy. \"We are moving forward expeditiously to complete the BLA for mirvetuximab, with the goal of submitting the application to FDA for accelerated approval in the first quarter of 2022. In parallel, commercial preparations are well underway to support the potential launch of mirvetuximab next year.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":143,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609675925"}
精彩评论